Apimeds Pharmaceuticals US, Inc. APUS
7.25
2.33
47.36%
as of 25 Sep
- Market cap
- $7.6M
- P/E
- 0.0×
Follow APUS
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Current Ratio |
3.42 | 0.01 | 1.31 |
Net Debt/EBITDA |
0.19 | (0.27) | 0.38 |
Debt/Assets |
63.23% | 2,647.33% | 4.32% |
Debt/Equity |
8.37 | (0.26) | 0.05 |
Asset Turnover |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.81 | 0.53 | 1.49 |
Capex/Depreciation |
— | — | (10.05) |
Interest Coverage |
0.00 | 0.00 | 0.00 |
| 0.00% | 209.62% | (7.90%) | |
| 0.00% | (638.79%) | (7.31%) | |
ROIC |
0.00% | 0.00% | (5.00%) |
Return on Tangible Assets |
(260.27%) | 137.46% | (180.27%) |
Research and Development Expense of Revenue |
0.00% | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.91 |
Share Based Compensation of Revenue |
0.00% | — | 0.00% |
Free Cash Flow per Share |
(1.37) | (0.93) | (8.25) |
Cash per Share |
0.89 | 0.00 | 10.69 |
Shareholders Equity per Share |
0.07 | (1.72) | 140.92 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.07 | (1.72) | 140.92 |
Free Cash Flow |
(0.63) | (0.73) | (8.98) |
Working Capital |
0.30 | (1.01) | 3.28 |
Capital Expenditures |
— | — | (0.06) |
Net Current Asset Value |
0.03 | (1.36) | 3.15 |
| Other line items | |||
Quick Ratio |
3.33 | 0.00 | 1.09 |
Depreciation/Fixed assets |
— | — | 0.11 |
Cash ROIC |
(88.51%) | 72.78% | (5.22%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.37) | (0.93) | (8.20) |
Capex per Share |
0.00 | 0.00 | (0.05) |
Average Payables |
— | 0.32 | 0.75 |
Average Assets |
— | 0.22 | 82.10 |
Average Common Equity |
— | (0.66) | 75.96 |
Capex to Sales |
— | — | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% |
Columns are period end dates